Author: Owen, Allison M.; Fults, Jessica B.; Patil, Naeem K.; Hernandez, Antonio; Bohannon, Julia K.
Title: TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection Cord-id: awnff2y1 Document date: 2021_2_18
ID: awnff2y1
Snippet: Despite advances in critical care medicine, infection remains a significant problem that continues to be complicated with the challenge of antibiotic resistance. Immunocompromised patients are highly susceptible to development of severe infection which often progresses to the life-threatening condition of sepsis. Thus, immunotherapies aimed at boosting host immune defenses are highly attractive strategies to ward off infection and protect patients. Recently there has been mounting evidence that
Document: Despite advances in critical care medicine, infection remains a significant problem that continues to be complicated with the challenge of antibiotic resistance. Immunocompromised patients are highly susceptible to development of severe infection which often progresses to the life-threatening condition of sepsis. Thus, immunotherapies aimed at boosting host immune defenses are highly attractive strategies to ward off infection and protect patients. Recently there has been mounting evidence that activation of the innate immune system can confer long-term functional reprogramming whereby innate leukocytes mount more robust responses upon secondary exposure to a pathogen for more efficient clearance and host protection, termed trained immunity. Toll-like receptor (TLR) agonists are a class of agents which have been shown to trigger the phenomenon of trained immunity through metabolic reprogramming and epigenetic modifications which drive profound augmentation of antimicrobial functions. Immunomodulatory TLR agonists are also highly beneficial as vaccine adjuvants. This review provides an overview on TLR signaling and our current understanding of TLR agonists which show promise as immunotherapeutic agents for combating infection. A brief discussion on our current understanding of underlying mechanisms is also provided. Although an evolving field, TLR agonists hold strong therapeutic potential as immunomodulators and merit further investigation for clinical translation.
Search related documents:
Co phrase search for related documents- adaptive innate and adjuvant vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- adaptive innate and adjuvant vaccine study: 1
- adaptive innate and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- adaptive innate and live virus vaccine: 1, 2, 3, 4, 5, 6
- adaptive innate and liver cancer: 1
- adaptive innate and local systemic: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and long term functional: 1
- adaptive innate and long term memory: 1, 2
- adaptive innate and low density: 1, 2
- adaptive innate and low density lipoprotein: 1
- adaptive innate and lps stimulation: 1, 2
- adaptive innate and lrr leucine rich repeat: 1
- adaptive innate and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- adaptive innate and lung viral load: 1, 2
- adaptive innate and lymphocyte response: 1, 2, 3, 4, 5, 6
- adaptive innate and macrophage activating: 1, 2, 3, 4
- adaptive innate and macrophage inflammatory: 1, 2, 3, 4, 5
- adaptive innate and macrophage neutrophil: 1, 2, 3
- adaptive innate and macrophage recruitment: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date